Stockreport

Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA

Veru Inc.  (VERU) 
Last veru inc. earnings: 2/12 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: verupharma.com/investors
PDF — VERU-100 Is a Proprietary Peptide Formulation Designed with Multiple Beneficial Clinical Attributes Addressing the Shortfalls of the Current Multi-Billion-Dollar Andro [Read more]